Israel - engelsk - Ministry of Health

novo nordisk ltd., israel - nonacog beta pegol - powder and solvent for solution for injection - nonacog beta pegol 1000 iu/vial - coagulation factor ix - treatment and prophylaxis of bleeding in pretreated patients with haemophilia b (congenital factor ix deficiency).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 500 iu/ml - injection, solvent for - excipient ingredients: sodium hydroxide; hydrochloric acid; histidine; water for injections - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 250 iu/ml - injection, solvent for - excipient ingredients: hydrochloric acid; sodium hydroxide; histidine; water for injections - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 125 iu/ml - injection, solvent for - excipient ingredients: histidine; water for injections; sodium hydroxide; hydrochloric acid - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 3000 iu - injection, solvent for - excipient ingredients: sodium chloride; water for injections - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 500 iu - injection, solvent for - excipient ingredients: sodium chloride; water for injections - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 1000 iu - injection, solvent for - excipient ingredients: water for injections; sodium chloride - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 2000 iu - injection, solvent for - excipient ingredients: water for injections; sodium chloride - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 1500 iu - injection, solvent for - excipient ingredients: sodium chloride; water for injections - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - not applicable